Everything below concerns Enzymatic hydrolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with enzymes or, less often, acid or heat to break peptide bonds. The starting material is typically sweet whey or acid whey from cheese making, first concentrated and dried into whey protein concentrate or isolate. Hydrolysis shortens long protein chains into smaller peptides, changing functional properties such as solubility, viscosity, and foam formation. The resulting powder contains peptides, residual intact protein, moisture, minerals, and variable amounts of lactose and fat depending on the starting material.
Enzymatic hydrolysis usually uses proteases from microbial, plant, or animal sources. The enzyme choice, pH, temperature, and reaction time determine which peptide bonds are cleaved and the final peptide profile. After hydrolysis, the enzyme is inactivated by heat, and the mixture is clarified, filtered, concentrated, and spray-dried. Manufacturers may use ultrafiltration to remove larger peptides or minerals. The degree of hydrolysis, often reported as a percentage, describes the proportion of peptide bonds broken. A higher degree generally means shorter peptides, but it does not by itself define taste, allergenicity, or biological activity.
Analytical control focuses on protein content, hydrolysis extent, molecular weight distribution, and residual intact protein. Kjeldahl or Dumas methods measure total nitrogen, while size-exclusion chromatography or mass spectrometry estimates peptide profiles. Sodium dodecyl sulfate polyacrylamide gel electrophoresis can show remaining intact proteins, though small peptides may not resolve. Enzyme-linked immunosorbent assays are used to assess residual allergenic proteins in some contexts. Because no single method captures all relevant features, manufacturers combine several assays and report values against internal specifications.
Stability depends on moisture, temperature, oxygen, and packaging. Powdered hydrolysate generally requires cool, dry storage and protection from humidity because peptides can absorb water and undergo Maillard reactions with residual lactose. Higher temperatures can increase bitterness, discoloration, and loss of solubility over time, while liquid hydrolysate formats are more perishable and may need refrigeration or preservatives. Shelf-life studies typically monitor moisture, color, pH, protein solubility, and microbial counts. Exact stability limits vary by peptide profile, packaging, and water activity, so general rules should be treated as approximate.
Industrial production begins with whey protein concentrate or isolate dispersed in water. Selected proteases, such as trypsin, pepsin, or microbial enzymes, are added under controlled pH and temperature. Hydrolysis continues until a target hydrolysis level is reached, after which heat or pH adjustment inactivates the enzyme. Ultrafiltration, diafiltration, and ion exchange may remove larger peptides, salts, or residual lactose. The liquid is then concentrated and spray-dried into powder. Processing choices influence peptide size, bitterness, mineral content, and microbial quality.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to cream powder | Color can vary with starting whey and drying conditions |
| Protein content | Typically 70-90% dry basis | Depends on whether concentrate or isolate is used |
| Degree of hydrolysis | Often 5-30% for commercial hydrolysates | Ranges vary by intended application and process |
| Solubility | High in water at neutral pH | Smaller peptides generally dissolve more readily than intact protein |
| Common synonyms | Hydrolyzed whey protein; whey peptide | Terms are not always standardized across suppliers |
Dried hydrolysate powders are usually off-white to pale yellow and are marketed as free-flowing powders or liquid concentrates. They are used in foods, beverages, and specialized nutrition products where rapid dispersion or reduced allergenicity is desired, although residual allergenic epitopes can remain depending on hydrolysis extent. The term hydrolysate does not imply a single molecular weight cutoff or a guaranteed clinical effect. Labels may state degree of hydrolysis, protein content, or peptide length profile, but analytical definitions vary across suppliers and jurisdictions.
Whey protein hydrolysate is a dairy ingredient produced by treating whey protein concentrate or isolate with proteolytic enzymes, acids, or heat under controlled conditions. The process cleaves peptide bonds and reduces average peptide size compared with intact whey proteins. Products are often described by degree of hydrolysis, which estimates the percentage of peptide bonds broken. Hydrolysates occupy a distinct category from concentrates and isolates because their peptide profile, solubility, and taste differ, even when the parent protein source is similar. Commercial production typically begins with pasteurized whey, followed by filtration, enzymatic treatment, inactivation, and drying.
Enzyme choice, pH, temperature, time, and substrate concentration influence the resulting peptide distribution. Endopeptidases cut internal peptide bonds, while exopeptidases remove terminal amino acids and can reduce bitterness. Manufacturers may combine enzymes or use membrane filtration to select peptide size ranges. A higher degree of hydrolysis generally means more small peptides and free amino acids, but it does not by itself define biological activity or nutritional quality. Batch-to-batch variation arises from raw whey composition, enzyme specificity, and processing parameters, so specification ranges are common in commercial supply.
Storage stability depends on moisture, temperature, and packaging. Dry powders with low water activity resist microbial growth, but they can still absorb water, develop off-colors through Maillard reactions, or oxidize residual lipids. Sealed containers kept in a cool, dry place are standard. Stability studies typically monitor moisture, solubility, color, peptide size, and microbial counts over months. Established practice favors low humidity and moderate temperatures. How brief excursions above recommended conditions affect peptide profiles and sensory qualities is less predictable and may depend on the specific product matrix.
Laboratories characterize hydrolyzed whey protein with several complementary assays. Total nitrogen methods, such as Kjeldahl or Dumas, estimate protein content using a dairy conversion factor. Free amino group assays, including TNBS and OPA, track the extent of peptide-bond cleavage. Size-exclusion chromatography and reversed-phase HPLC reveal peptide size distributions and hydrophobicity. Mass spectrometry can identify specific peptides, while amino acid analysis quantifies individual residues. No single test captures every relevant property, so results are usually interpreted together with process records and specification limits.
Enzyme choice influences the peptide size distribution and the resulting functional properties. Some proteases cut at specific amino acid residues, while others act more broadly, so two hydrolysates with the same degree of hydrolysis can differ in peptide sequences. Short peptides are generally more water-soluble and less likely to form gels under heat, although bitterness can increase when hydrophobic residues become exposed. The relationship between peptide length, taste, and bioactivity is an active area of study, and not all proposed effects are established in human trials.
Composition tables often report protein content on a dry basis, ash, moisture, fat, and lactose. Because hydrolysis adds water to peptide bonds, the total mass yield can appear slightly higher than the original protein if residual salts and water are counted. Some products are further processed by ultrafiltration, spray drying, or decolorization, which alters mineral content and flavor. Product labels may distinguish partially hydrolyzed from extensively hydrolyzed whey, but these terms are not always defined by a single numerical threshold across regions.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with proteases that cleave peptide bonds. The starting material is typically whey protein concentrate or isolate, which contains beta-lactoglobulin, alpha-lactalbumin, and smaller amounts of bovine serum albumin and immunoglobulins. Hydrolysis shortens protein chains into peptides and free amino acids, changing solubility, viscosity, and flavor compared with intact whey protein. The extent of cleavage is commonly described by degree of hydrolysis, a percentage of broken peptide bonds relative to total bonds.
Hydrolysates are generally stable as dry powders but can absorb moisture and undergo browning during warm storage. The bitter taste of some hydrolysates arises from hydrophobic peptides exposed by cleavage, and it varies with enzyme choice and degree of hydrolysis. Reduced allergenicity is sometimes claimed, but residual IgE-binding peptides may remain, especially in partial hydrolysates. Regulatory frameworks treat extensively hydrolyzed and partially hydrolyzed products differently, and labeling rules vary by country. More research is needed on how specific peptide profiles relate to clinical outcomes.
Commercial production begins with whey protein concentrate or isolate dissolved in water. A protease is added under controlled pH and temperature, and the reaction is stopped by heat or pH adjustment once a target degree of hydrolysis is reached. Membrane filtration, often ultrafiltration or diafiltration, removes enzymes and small solutes while retaining peptides. The liquid is then concentrated and spray-dried into a powder. Each step influences peptide length, mineral content, and flavor.
The society publishes three research journals and a review journal: the Journal of Pharmacology and Experimental Therapeutics, Drug Metabolism and Disposition, Molecular Pharmacology, and Pharmacological Reviews Starting in 2012 these publications are only offered online. The society copublishes a wholly open access journal with the British Pharmacological Society and Wiley entitled Pharmacology Research & Perspectives. ASPET also publishes a quarterly newsletter, The Pharmacologist, and, from 2001 to 2011, Molecular Interventions magazine. The society gives out several awards:
Translocation: The receptor is, along with the part of the membrane it is embedded in, brought to the inside of the cell, where it is dephosphorylated within the acidic vesicular environment and then brought back. This mechanism is used to regulate long-term exposure, for example, to a hormone, by allowing resensitisation to follow desensitisation. Alternatively, the receptor may undergo lysosomal degradation, or remain internalised, where it is thought to participate in the initiation of signalling events, the nature of which depending on the internalised vesicle's subcellular localisation. Arrestin linking: The phosphorylated receptor can be linked to arrestin molecules that prevent it from binding (and activating) G proteins, in effect switching it off for a short period of time. This mechanism is used, for example, with rhodopsin in retina cells to compensate for exposure to bright light. In many cases, arrestin's binding to the receptor is a prerequisite for translocation. For example, beta-arrestin bound to β2-adrenoreceptors acts as an adaptor for binding with clathrin, and with the beta-subunit of AP2 (clathrin adaptor molecules); thus, the arrestin here acts as a scaffold assembling the components needed for clathrin-mediated endocytosis of β2-adrenoreceptors.
A disintegrin and metalloproteinase with thrombospondin motifs 7 (ADAMTS7) is an enzyme that in humans is encoded by the ADAMTS7 gene on chromosome 15. It is ubiquitously expressed in many tissues and cell types. This enzyme was historically reported to catalyze the degradation of cartilage oligomeric matrix protein (COMP), though subsequent studies using purified proteins and unbiased mass spectrometry found that ADAMTS7 does not cleave COMP. ADAMTS7 has been associated with cancer and arthritis in multiple tissue types. The ADAMTS7 gene is a well-established genetic susceptibility locus for coronary artery disease. The ADAMTS7 gene resides on chromosome 15 at the band 15q24.2 and contains 25 exons.
The topology of a β-sheet describes the order of hydrogen-bonded β-strands along the backbone. For example, the flavodoxin fold has a five-stranded, parallel β-sheet with topology 21345; thus, the edge strands are β-strand 2 and β-strand 5 along the backbone. Spelled out explicitly, β-strand 2 is H-bonded to β-strand 1, which is H-bonded to β-strand 3, which is H-bonded to β-strand 4, which is H-bonded to β-strand 5, the other edge strand. In the same system, the Greek key motif described above has a 4123 topology. The secondary structure of a β-sheet can be described roughly by giving the number of strands, their topology, and whether their hydrogen bonds are parallel or antiparallel. β-sheets can be open, meaning that they have two edge strands (as in the flavodoxin fold or the immunoglobulin fold) or they can be closed β-barrels (such as the TIM barrel). β-Barrels are often described by their stagger or shear. Some open β-sheets are very curved and fold over on themselves (as in the SH3 domain) or form horseshoe shapes (as in the ribonuclease inhibitor). Open β-sheets can assemble face-to-face (such as the β-propeller domain or immunoglobulin fold) or edge-to-edge, forming one big β-sheet.
Sources: en.wikipedia.org
thio-phosphorylated derivatives of resorcinols and calixarenes; studying thio-phosphorylated unsaturated compounds using petrochemical and wood-chemical feedstock; generation and theoretical study of phosphabetains and their derivatives (phosphonium salts, carboxyl-containing metal complexes); searching for liquid growth-boosting fertilizer compounds based on microelements. The following majors are currently offered to students: 04.03.01 Chemistry, Bachelor's degree program; 04.05.01 Fundamental and Applied Chemistry, Specialist Degree program; 04.04.01 Chemistry, Master's degree program; 44.03.01 Pedagogical Education, Bachelor's degree program. The following master's degree programs are offered by the Institute in the academic year 2015–2016:
2051–2084. Federal regulations associated with the act are at Title 16 CFR parts 1101 through 1406. These regulations are numerous and include such laws as the Poison Prevention Packaging Act (PPPA), safety standards for such products as bicycle helmets and cigarette lighters, a ban on lead in paint, and a rule concerning size requirements for toys that could be choking hazards for young children.
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup A10 is part of the anatomical group A Alimentary tract and metabolism. Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QA10. National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version. A10AB01 Insulin (human) A10AB02 Insulin (beef) A10AB03 Insulin (pork) A10AB04 Insulin lispro A10AB05 Insulin aspart A10AB06 Insulin glulisine A10AB30 Combinations === A10AC Insulins and analogues for injection, intermediate-acting === A10AC01 Insulin (human) A10AC02 Insulin (beef) A10AC03 Insulin (pork) A10AC04 Insulin lispro A10AC30 Combinations
The transduction of the signal through the membrane by the receptor is not completely understood. It is known that in the inactive state, the GPCR is bound to a heterotrimeric G protein complex. Binding of an agonist to the GPCR results in a conformational change in the receptor that is transmitted to the bound Gα subunit of the heterotrimeric G protein via protein domain dynamics. The activated Gα subunit exchanges GTP in place of GDP which in turn triggers the dissociation of Gα subunit from the Gβγ dimer and from the receptor. The dissociated Gα and Gβγ subunits interact with other intracellular proteins to continue the signal transduction cascade while the freed GPCR is able to rebind to another heterotrimeric G protein to form a new complex that is ready to initiate another round of signal transduction. It is believed that a receptor molecule exists in a conformational equilibrium between active and inactive biophysical states. The binding of ligands to the receptor may shift the equilibrium toward the active receptor states. Three types of ligands exist: Agonists are ligands that shift the equilibrium in favour of active states; inverse agonists are ligands that shift the equilibrium in favour of inactive states; and neutral antagonists are ligands that do not affect the equilibrium. It is not yet known how exactly the active and inactive states differ from each other.
Understanding of the molecular basis of binding to integrins has enabled the development of several drugs for cardiovascular disease and cancer, including eptifibatide, tirofiban and cilengitide. These drugs inhibit integrin binding. PET radiotracers such as fluciclatide utilize RGD-containing peptides to home to tumors, allowing for cancer monitoring. Eptifibatide and tirofiban are anti-clotting drugs indicated to prevent thrombosis in acute ischemic coronary syndromes. Eptifibatide is additionally FDA approved for patients undergoing percutaneous coronary intervention. These drugs block activation of the integrin responsible for aggregation of platelets (αIIbβ3, also known as glycoprotein IIb/IIIa) in response to the blood glycoproteins fibrinogen and von Willebrand factor. Eptifibatide (marketed as Integrilin) is a cyclic (circular) seven amino acid peptide, whereas tirofiban is a small molecule designed to mimic the chemistry and binding affinity of the RGD sequence.
Sources: en.wikipedia.org
Topical nonsteroidal anti-inflammatory drugs provide pain relief in common conditions such as muscle sprains and overuse injuries. Since the side effects are also lesser, topical preparations could be preferred over oral medications in these conditions. Some novel and investigational analgesics include subtype-selective voltage-gated sodium channel blockers such as funapide and raxatrigine, as well as multimodal agents such as ralfinamide. Audioanalgesia Electroanalgesia Pain management Patient-controlled analgesia Pain in babies Congenital analgesia (insensitivity to pain)
The topology of a β-sheet describes the order of hydrogen-bonded β-strands along the backbone. For example, the flavodoxin fold has a five-stranded, parallel β-sheet with topology 21345; thus, the edge strands are β-strand 2 and β-strand 5 along the backbone. Spelled out explicitly, β-strand 2 is H-bonded to β-strand 1, which is H-bonded to β-strand 3, which is H-bonded to β-strand 4, which is H-bonded to β-strand 5, the other edge strand. In the same system, the Greek key motif described above has a 4123 topology. The secondary structure of a β-sheet can be described roughly by giving the number of strands, their topology, and whether their hydrogen bonds are parallel or antiparallel. β-sheets can be open, meaning that they have two edge strands (as in the flavodoxin fold or the immunoglobulin fold) or they can be closed β-barrels (such as the TIM barrel). β-Barrels are often described by their stagger or shear. Some open β-sheets are very curved and fold over on themselves (as in the SH3 domain) or form horseshoe shapes (as in the ribonuclease inhibitor). Open β-sheets can assemble face-to-face (such as the β-propeller domain or immunoglobulin fold) or edge-to-edge, forming one big β-sheet.
As a prototypical transaminase, AST relies on PLP (vitamin B6) as a cofactor to transfer the amino group from aspartate or glutamate to the corresponding ketoacid. In the process, the cofactor shuttles between PLP and the pyridoxamine phosphate (PMP) form. The amino group transfer catalyzed by this enzyme is crucial in both amino acid degradation and biosynthesis. In amino acid degradation, following the conversion of α-ketoglutarate to glutamate, glutamate subsequently undergoes oxidative deamination to form ammonium ions, which are excreted as urea. In the reverse reaction, aspartate may be synthesized from oxaloacetate, which is a key intermediate in the citric acid cycle. Two isoenzymes are present in a wide variety of eukaryotes. In humans:
APHL works with public health partners to build the foundation for quality testing, comprehensive standards and integrated public health laboratory systems. One of the initiatives, the Laboratory System Improvement Program, provides individual assessments of public health laboratory systems that include engaging stakeholders for system improvement, performance, implementation of strategies and continual evaluation. APHL also collaborates on the National Laboratory System project to build a public-private network of laboratories nationwide. APHL monitors trends in public health laboratory diagnostics, personnel and infrastructure in order to create quality assurance standards. By using these data points to benchmark individual labs against national norms, APHL is able to home in on key issues and help raise the standard of laboratory systems. Member labs have access to research and survey data online, which enables them to leverage new information quickly to identify promising strategies and practices.
Actin, gamma-enteric smooth muscle is a protein that in humans is encoded by the ACTG2 gene. Actins are highly conserved proteins that are involved in various types of cell motility, and maintenance of the cytoskeleton. In vertebrates, three main groups of actin isoforms, alpha, beta and gamma have been identified. The alpha actins are found in muscle tissues and are a major constituent of the contractile apparatus. The beta and gamma actins co-exist in most cell types as components of the cytoskeleton, and as mediators of internal cell motility. Actin, gamma 2, encoded by this gene, is a smooth muscle actin found in enteric tissues. ACTG2 has been shown to interact with Emerin. Human ACTG2 genome location and ACTG2 gene details page in the UCSC Genome Browser.
Sources: en.wikipedia.org
It is whey protein that has been partially broken down into smaller peptides through hydrolysis. The powder still contains a mixture of peptides, residual protein, minerals, and other whey components. It is used as a food ingredient rather than a single pure compound.
Proteases cleave peptide bonds, reducing molecular size and altering solubility, viscosity, and taste. The extent of change depends on the enzyme and reaction conditions. Hydrolysis does not remove all intact protein or guarantee a specific peptide profile.
Degree of hydrolysis is the percentage of peptide bonds cleaved during the reaction. It is a processing measure, not a direct measure of peptide size distribution or function. Two products with the same degree can still differ in peptide sequence and sensory properties.
Hydrolysis extent is often estimated by measuring the increase in soluble nitrogen or free amino groups relative to total nitrogen. The o-phthaldialdehyde method and trinitrobenzenesulfonic acid assay are common laboratory approaches. Values are method-dependent, so comparisons require the same assay and calculation.